deltatrials
Completed PHASE2 INTERVENTIONAL NCT00330070

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids

Sponsor: Inflazyme Pharmaceuticals Ltd

Conditions Asthma
Interventions IPL512,602 20 mg once daily IPL512,602 Matching Placebo once daily
Updated 5 times since 2017 Last updated: Feb 14, 2007 Started: May 31, 2006 Completion: Jan 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by Inflazyme Pharmaceuticals Ltd and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Inflazyme Pharmaceuticals Ltd
Data source: Inflazyme Pharmaceuticals Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations